Tirzepatide, a recently approved drug , is sparking considerable interest within the medical community. This dual-action compound, functioning as both a GLP-1 agonist and a GIP receptor , demonstrates https://tirzepatide402108.newsyblog.com/3147258/tirzepatide-a-new-treatment-for-late-onset-glucose-intolerance